Fund V, L.P.Omega Fund V Gp... Net Worth

The estimated Net Worth of Fund V, L.P.Omega Fund V Gp... is at least $169 Million dollars as of 1 July 2019. Fund Gp owns over 133,333 units of Morphic Inc stock worth over $169,236,478 and over the last 5 years Fund sold MORF stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Fund Gp MORF stock SEC Form 4 insiders trading

Fund has made over 1 trades of the Morphic Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Fund bought 133,333 units of MORF stock worth $1,999,995 on 1 July 2019.

The largest trade Fund's ever made was buying 133,333 units of Morphic Inc stock on 1 July 2019 worth over $1,999,995. On average, Fund trades about 133,333 units every 0 days since 2019. As of 1 July 2019 Fund still owns at least 2,969,582 units of Morphic Inc stock.

You can see the complete history of Fund Gp stock trades at the bottom of the page.

Insiders trading at Morphic Inc

Over the last 5 years, insiders at Morphic Inc have traded over $69,316,197 worth of Morphic Inc stock and bought 3,360,997 units worth $101,882,696 . The most active insiders traders include Plc Gsk, Holdings A/S Novo, and Timothy A Springer. On average, Morphic Inc executives and independent directors trade stock every 13 days with the average trade being worth of $2,254,353. The most recent stock trade was executed by Bruce Rogers on 8 July 2024, trading 20,000 units of MORF stock currently worth $86,400.

What does Morphic Inc do?

oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.

Complete history of Fund Gp stock trades at Morphic Inc

Morphic Inc executives and stock owners

Morphic Inc executives and other stock owners filed with the SEC include:

• Timothy Springer,
  Founder, Independent Director
• Alexey Lugovskoy,
  Chief Development Officer
• Dr. Praveen P. Tipirneni M.D.,
  CEO, Pres & Director
• William DeVaul,
  General Counsel, Secretary
• Praveen Tipirneni,
  President, Chief Executive Officer, Director
• Dr. Marc Schegerin M.B.A., M.D.,
  CFO & COO
• Bruce Rogers,
  Chief Scientific Officer
• Vikas Goyal,
  Independent Director
• Gustav Christensen,
  Independent Chairman of the Board
• Joseph Slattery,
  Independent Director
• Otello Stampacchia,
  Independent Director
• Norbert Bischofberger,
  Independent Director
• Amir Nashat,
  Independent Director
• Dr. Timothy A. Springer Ph.D.,
  Founder, Independent Director & Member of Scientific Advisory Board
• Nilesh Kumar,
  Independent Director
• Peter Linde,
  Chief Medical Officer
• Robert Farrell,
  Senior Vice President - Finance, Chief Accounting Officer
• Marc Schegerin,
  Chief Financial Officer, Chief Operating Officer
• Adrian S. Ray Ph.D.,
  Sr. VP and Head of Biology & Translation
• Blaise Lippa,
  Sr. VP of Molecular Discovery
• William D. DeVaul Esq.,
  Gen. Counsel & Sec.
• Dr. Bruce N. Rogers,
  Chief Scientific Officer
• Robert E. Farrell Jr., CPA, CPA,
  Sr. VP of Fin./Operations & Chief Accounting Officer
• Susannah Gray,
  
• Nisha Nanda,
  
• Martin Edwards,
  
• Holdings A/S Novo,
  10% owner
• Plc Gsk,
  Director
• Otello Stampacchia,
  Director
• Fund V, L.P.Omega Fund V Gp...,
  
• Simon Peter Cooper,
  CMO